Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

The U.S. State Department has approved the potential sale of F-16 training and sustainment, along with related equipment, for ...

The U.S. Food and Drug Administration is asking some of its recently fired staff responsible for critically important funding ...

The top sustainable finance executive at HSBC's asset management division is leaving the firm, HSBC said on Friday, the ...

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

Health Secretary Robert F. Kennedy Jr. will testify before the U.S. Senate's health committee on May 14, the panel said on ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Britain's blue-chip index notched its 15th consecutive session of gains - its longest winning streak on record - as investors ...

The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first ...

Euroclear plans to seize and redistribute about 3 billion euros ($3.4 billion) of Russia's funds that are frozen at the ...

In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...